Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab

Pembrolizumab is an immune checkpoint inhibitor used in many cancer types, including genitourinary cancers. Although immunotherapies have dramatically changed the landscape of cancer treatment by providing an alternative to traditional chemotherapy, they have been associated with significant immune-...

Descripción completa

Detalles Bibliográficos
Autores principales: McCormick, Benjamin Joseph, Zieman, Daniel, West-Santos, Cassidy, Phillips, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Case Reports: Adverse drug reactions and complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314548/
https://www.ncbi.nlm.nih.gov/pubmed/37339826
http://dx.doi.org/10.1136/bcr-2023-254692
_version_ 1785067331696721920
author McCormick, Benjamin Joseph
Zieman, Daniel
West-Santos, Cassidy
Phillips, Michael B
author_facet McCormick, Benjamin Joseph
Zieman, Daniel
West-Santos, Cassidy
Phillips, Michael B
author_sort McCormick, Benjamin Joseph
collection PubMed
description Pembrolizumab is an immune checkpoint inhibitor used in many cancer types, including genitourinary cancers. Although immunotherapies have dramatically changed the landscape of cancer treatment by providing an alternative to traditional chemotherapy, they have been associated with significant immune-related adverse events (IRAEs) with wide-ranging clinical manifestations. We present the case of an elderly woman on pembrolizumab for metastatic bladder cancer who developed cutaneous IRAE with lichenoid eruptions that responded to high-dose intravenous glucocorticoids.
format Online
Article
Text
id pubmed-10314548
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103145482023-07-02 Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab McCormick, Benjamin Joseph Zieman, Daniel West-Santos, Cassidy Phillips, Michael B BMJ Case Rep Case Reports: Adverse drug reactions and complications Pembrolizumab is an immune checkpoint inhibitor used in many cancer types, including genitourinary cancers. Although immunotherapies have dramatically changed the landscape of cancer treatment by providing an alternative to traditional chemotherapy, they have been associated with significant immune-related adverse events (IRAEs) with wide-ranging clinical manifestations. We present the case of an elderly woman on pembrolizumab for metastatic bladder cancer who developed cutaneous IRAE with lichenoid eruptions that responded to high-dose intravenous glucocorticoids. BMJ Publishing Group 2023-06-20 /pmc/articles/PMC10314548/ /pubmed/37339826 http://dx.doi.org/10.1136/bcr-2023-254692 Text en © BMJ Publishing Group Limited 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Reports: Adverse drug reactions and complications
McCormick, Benjamin Joseph
Zieman, Daniel
West-Santos, Cassidy
Phillips, Michael B
Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title_full Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title_fullStr Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title_full_unstemmed Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title_short Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
title_sort immune checkpoint inhibitor lichenoid eruption due to pembrolizumab
topic Case Reports: Adverse drug reactions and complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314548/
https://www.ncbi.nlm.nih.gov/pubmed/37339826
http://dx.doi.org/10.1136/bcr-2023-254692
work_keys_str_mv AT mccormickbenjaminjoseph immunecheckpointinhibitorlichenoideruptionduetopembrolizumab
AT ziemandaniel immunecheckpointinhibitorlichenoideruptionduetopembrolizumab
AT westsantoscassidy immunecheckpointinhibitorlichenoideruptionduetopembrolizumab
AT phillipsmichaelb immunecheckpointinhibitorlichenoideruptionduetopembrolizumab

Ejemplares similares